Author: admin

  • Willis Lease Finance Corporation Announces Aircraft Engine Leasing Partnership with Blackstone Credit & Insurance

    Willis Lease Finance Corporation Announces Aircraft Engine Leasing Partnership with Blackstone Credit & Insurance

    COCONUT CREEK, Fla. and NEW YORK — January 5, 2026 — Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC” or the “Company”), the leading lessor of commercial aircraft engines and a global provider of aviation services, and Blackstone Credit & Insurance (“BXCI”) announced a strategic aircraft engine leasing partnership with plans to deploy over $1 billon in the next two years in current and next generation aircraft engines and select aircraft. This unique partnership brings together a leading engine leasing specialist with Blackstone’s scaled private credit business to focus on the engine asset class.
     
    The partnership leverages WLFC’s established position as a pioneer in aircraft engine leasing and its growing asset management platform. WLFC has identified a seed portfolio and near-term pipeline of high-quality engine assets that are expected to close into the partnership, providing immediate scale and diversification across engine types and airline customers globally.
     
    “We are excited to partner with BXCI, whose scale and long-term capital commitment will accelerate the growth of our asset management business,” said Austin C. Willis, CEO of WLFC. “Blackstone is a leader in asset-based credit, and their investment demonstrates the strength of our position in aircraft engine leasing and their belief in our ability to generate attractive returns through disciplined asset selection and active management.”
     
    Scott Flaherty, CFO of WLFC, added “the Blackstone relationship provides further capital diversification to the Willis platform. We are excited about this new relationship and the growth opportunities this brings to our business.”
     
    “Willis is a leading lessor of commercial aircraft engines and brings unparalleled technical expertise, deep customer relationships and a proven track record,” said Aneek Mamik, Senior Managing Director, Blackstone Credit & Insurance. “This opportunity is consistent with BXCI’s objectives of building programmatic, differentiated origination in large addressable markets with a focus on hard assets and strong downside protection.”
     
    “We look forward to partnering with the WLFC team to support the growth of their platform and deliver essential engine solutions for the global aviation fleet,” added Alex Buck, Principal, Blackstone Credit & Insurance.
     
    BXCI’s Infrastructure and Asset Based Credit group manages over $100 billion and has over 80 investment professionals, as of September 30, 2025. The platform is focused on providing investment grade credit, non-investment grade credit, and structured investments across the real economy in sectors such as infrastructure, commercial finance, fund finance, consumer finance, and residential real estate loans.
     
    BNP Paribas served as sole structuring agent and advisor to BXCI.
     
    About Willis Lease Finance Corporation
    Willis Lease Finance Corporation leases large and regional spare commercial aircraft engines, auxiliary power units and aircraft to airlines, aircraft engine manufacturers and maintenance, repair and overhaul providers worldwide. These leasing activities are integrated with various end-of-life solutions for engines and aviation materials provided through Willis Aeronautical Services, Inc. Additionally, through Willis Engine Repair Center®, Jet Centre by Willis, and Willis Aviation Services Limited, the Company’s service offerings include Part 145 engine maintenance, aircraft line and base maintenance, aircraft disassembly, parking and storage, airport FBO and ground and cargo handling services. Willis Sustainable Fuels intends to develop, build and operate projects to help decarbonize aviation.
     
    About Blackstone Credit & Insurance
    Blackstone Credit & Insurance (“BXCI”) is one of the world’s leading credit investors. Our investments span the credit markets, including private investment grade, asset-based lending, public investment grade and high yield, sustainable resources, infrastructure debt, collateralized loan obligations, direct lending and opportunistic credit. We seek to generate attractive risk-adjusted returns for institutional and individual investors by offering companies capital needed to strengthen and grow their businesses. BXCI is also a leading provider of investment management services for insurers, helping those companies better deliver for policyholders through our world-class capabilities in investment grade private credit.
     
    Contacts
    Willis Lease Finance Corporation
    Lynn Kohler
    [email protected]
    (415) 328-4798
     
    Blackstone
    David Vitek
    [email protected]
    (212) 583-5291

    Continue Reading

  • Carina Nebula shines with white-blue stars photo of the day for Jan. 5, 2026

    Carina Nebula shines with white-blue stars photo of the day for Jan. 5, 2026

    Recently, the James Webb Space Telescope (JWST) took a stunning image of the star cluster known as Westerlund 2, located in a stellar nursery called Gum 29 found within the Carina Nebula. The cluster is 6-to-13 light-years across and has some…

    Continue Reading

  • Weather Competition Winter 2026

    Weather Competition Winter 2026


    Continue Reading

  • Greenland says ‘no more fantasies about annexation’ after Trump remarks – Dawn

    1. Greenland says ‘no more fantasies about annexation’ after Trump remarks  Dawn
    2. ‘We need Greenland’: Trump repeats threat to annex Danish territory  BBC
    3. US attack on Greenland would mean end of Nato, says Danish PM  The Guardian
    4. Denmark in…

    Continue Reading

  • Why Public Health Experts Are Nervous About Bird Flu Right Now?

    Why Public Health Experts Are Nervous About Bird Flu Right Now?

    For years, there has been an unspoken rule in newsrooms: avoid pandemic stories unless something is already on fire. COVID exhausted public attention, political patience, and institutional credibility.

    When the emergency phase ended, many…

    Continue Reading

  • Best Pokémon TCG deal: Cynthia’s Garchomp ex Premium Collection is below market value at Amazon

    Best Pokémon TCG deal: Cynthia’s Garchomp ex Premium Collection is below market value at Amazon

    BELOW MARKET VALUE: The Pokémon TCG Cynthia’s Garchomp ex Premium Collection is currently $54.44 on Amazon, which is down to market value when compared to TCGplayer listings starting…

    Continue Reading

  • Bloch, M.E. and J.G. Schneider. M.E. Blochii, Systema ichthyologiae iconibus CX illustratum. Vol. [Atlas]. Berolini: Sumtibus auctoris impressum et Bibliopolio Sanderiano commissum. (Bavarian State Library, 1801).

  • Nielsen, J. et al. Eye lens…

Continue Reading

  • Advancing Research and Combatting Disparities in Pancreatic Cancer Care

    Advancing Research and Combatting Disparities in Pancreatic Cancer Care

    In a conversation with CancerNetwork®, Jose G. Trevino, II, MD, FACS, spoke about the current state of the pancreatic ductal adenocarcinoma (PDAC) paradigm as well as next steps for improving the prognosis of patients…

    Continue Reading

  • Tovorafenib Produces Prolonged Clinical Stability and Durability in R/R pLGG

    Tovorafenib Produces Prolonged Clinical Stability and Durability in R/R pLGG

    Tovorafenib (Ojemda) has further solidified its place in the treatment landscape of relapsed/refractory pediatric low-grade glioma (pLGG) following updated data from the phase 2 FIREFLY-1 trial (NCT04775485), according to Cassie Kline, MD, MAS.

    Findings from the updated 3-year analysis of FIREFLY-1 presented during the 2025 Society of Neuro-Oncology Annual Meeting demonstrated that efficacy-evaluable patients with relapsed/refractory pLGG who received tovorafenib in arm 1 (n = 76) achieved an overall response rate (ORR) of 53%.1 The median duration of response (DOR) was 19.4 months (95% CI, 13.8-27.2) and the median time to response was 5.4 months (range, 1.6-17.5). The median time to next treatment (TTNT) was 42.6 months (95% CI, 36.7-not estimable).

    “We were able to identify a very long period of TTNT [with] additional follow-up, [with] no new safety signals,” Kline said in an interview in OncLive®. “We now have a cohort, although [it’s] still small numbers, that have also entered a retreatment arm after coming off of the drug and seeing tumor changes that warranted retreatment. We were excited to see the response of the 3-year follow up data that are adding on to what was previously presented and published.”

    Updated Results From the Phase 2 FIREFLY-1 Trial

    • Efficacy-evaluable patients with relapsed/refractory pLGG who received tovorafenib in arm 1 (n = 76) achieved an ORR of 53%.
    • The median DOR was 19.4 months (95% CI, 13.8-27.2), the median time to response was 5.4 months (range, 1.6-17.5), and the median TTNT was 42.6 months (95% CI, 36.7-not estimable).
    • No new safety signals were identified.

    In the interview, Kline, an attending physician and director of clinical research in the Department of Neuro-Oncology at Children’s Hospital of Philadelphia in Pennsylvania, discussed the design of FIREFLY-1, the mechanism of action of tovorafenib, and the significance of the key findings from the study.

    OncLive: What was the rationale and study design characteristics of FIREFLY-1?

    Kline: The trial was designed for [patients with] recurrent pLGG. There’s also a solid tumor cohort. As a pediatric-neuro oncologist, I [am] focused on the pLGG cohort, [which] was designed to identify the clinical benefit and efficacy of tovarafinib.

    What is the mechanism of action of tovorafenib?

    Tovarafinib [is a] pan-RAF inhibitor. Many of our agents target a single step in the active pathways of these tumors, whereas as a pan RAF inhibitor, [tovarafinib] is targeting the pathway in its entirety. Another unique [characteristic of] the agent is that it’s once-weekly oral dosing, which is nice for patients and families in terms of quality of life.

    What prior data have been reported with tovorafenib?

    [Tovarafinib] seemed to provide clinical benefit and disease response in our patients with pLGG. That was promising in comparison with other agents that were currently being utilized in this setting.

    What were the key data that were shared in the 3-year update?

    The [median] TTNT being over 40 months is giving our patients and families a long period of not necessarily needing additional therapies. We also saw that most patients, once they stopped treatment after 26 cycles, were able to remain treatment-free for up to a year, and that the majority of patients too were able to finish the 26 cycles of therapy also. All of that is very promising in terms of the potential clinical benefit, the tolerability of this agent, and then, ideally, the ongoing disease control once the patients have come off of treatment.

    What are the next steps for this research?

    It’s going to continue to be to [monitor] these long-term outcomes in terms of how long we’re able to maintain disease control. There are other long term toxicities that we’re all interested in exploring as well. Those will really be critical next steps.

    Another question in the setting of pLGG is this question of rebound growth that can happen after targeted agents are stopped. We’re going to be very comprehensive in also exploring the incidence of rebound growth and what that means for our patients and families with tovorafenibspecifically

    In light of the updated data from FIREFLY-1, what is the current role of tovorafenib in pLGG?

    Right now, we’re in the setting of an FDA indication for recurrent disease.2 Many in our community are readily utilizing that [indication] and at the first step of disease recurrence or primary or upfront treatment failure. It’s certainly fitting nicely in that paradigm. There are ongoing studies that are exploring randomization between the agent with standard chemotherapy. [Determining] where this fits in the upfront treatment schema will be a next rational step as we’re thinking about how we’re utilizing this agent to treat our [patients].

    References

    1. Kline C, Hargrave D, Khong-Quang DA, et al. Clinical stability following tovorafenib treatment in relapsed/refractory pediatric low-grade glioma: updated results from the phase 2 FIREFLY-1 trial. Presented at 2025 Society of Neuro-Oncology Annual Meeting; November 19-23, 2025; Honolulu, HI. Abstract CTP-17.
    2. FDA grants accelerated approval to tovorafenib for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma. FDA. Updated May 22, 2024. Accessed January 2, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric

    Continue Reading

  • Scientific publisher agreements expand open-access research

    Scientific publisher agreements expand open-access research

    UNIVERSITY PARK, Pa. — Penn State University Libraries will enter into new open-access publishing agreements with two major scientific publishers starting in 2026. These contracts ensure that Penn State peer-reviewed research published through…

    Continue Reading